Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Anthony Bewley
Barts Health NHS Trust, London, UK
Professor Anthony Bewley, BA (Hons), FRCP, is a consultant dermatologist at Barts Health NHS Trust, London, UK, and an honorary professor at Queen Mary College (University of London). read more
He is fully trained in general dermatology, with a special interest in psychodermatology (psycho-cutaneous medicine). He is the lead for commercial clinical trials research at the Barts Health Dermatology Department, and has published extensively in international peer-reviewed journals on a range of different areas within dermatology. Prof. Bewley was chair of Psychodermatology UK 2008–2020; president of the UK Dowling Dermatology Club 2019–2020 and honorary treasurer of the British Association of Dermatologists (2019–2022). He is the co-editor of Practical Psychodermatology and Psychodermatology in Clinical Practice. He is president of the European Society for Dermatology and Psychiatry
Prof. Anthony Bewley discloses:Â Consulting or advisory board fees from AbbVie, Almirall, BMS, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi and UCB; Grants/research support from Janssen.
Prof. Martin Metz
Institute of Allergology (IFA), Charité – Universitätsmedizin Berlin, Germany
Martin Metz, MD, is a professor of dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin, Germany, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Department of Allergology and Immunology. read more
He received his medical education at the Free University of Berlin and the Humboldt University of Berlin. He specialized in dermatology at King’s College Hospital, London, UK, and the University of Mainz, Germany, and in experimental pathology at Beth Israel Deaconess Medical Centre and Harvard Medical School in Boston (1997–1998) and Stanford University (2004–2006) in the USA. He is board certified in dermatology and allergology, and is head of the specialty outpatient clinics for pruritus, head of translational research, and deputy head of clinical research at the Institute of Allergology, Charité – Universitätsmedizin Berlin. His main scientific areas of interest are mast cell biology, neuroimmunology, inflammation and innate immunity, with a major clinical and translational focus on pruritus and mast cell mediated diseases.
Prof. Martin Metz discloses: Speaker, consulting, advisory board or panel fees from Amgen (relationship ended), Celldex Therapeutics (relationship ended), Galderma and Sanofi-Aventis.
Dr Manuel Pereira
Institute of Allergology (IFA), Charité – Universitätsmedizin Berlin, Germany
Manuel P Pereira, MD, PhD, is dermatologist at the Institute of Allergology at the Charité – Universitätsmedizin Berlin, Germany, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Department of Allergology and Immunology. read more
He received his medical education at the University of Porto, Portugal, and at Charité – Universitätsmedizin Berlin. He completed his training in dermatology at the University Hospital Münster, Germany. Additionally, he obtained a PhD from the Neuroscience Graduate School at the University of Copenhagen, Denmark. His main research interests include translational and clinical research in chronic itch, chronic prurigo and atopic dermatitis.
Dr Manuel Pereira discloses: Speaker, consulting, advisory board or panel fees from AbbVie, Beiersdorf, Eli Lilly, GA2LEN, Galderma, Menlo Therapeutics, Novartis, Sanofi, Trevi Therapeutics and Unna Academy.
Ms Sailaja Maganti
Prurigo Nodularis International, London, UK
Ms Sailaja Maganti is the founder of Prurigo Nodularis International (PNI), London, UK. read more
With almost 20 years’ lived experience of prurigo nodularis (PN), Sailaja leads the largest global support group for patients with PN. With almost 5,000 subscribers, she is currently establishing PNI as a formal charity and will assume the roles of chair and trustee.
Having endured a 9-year rollercoaster of a diagnosis journey, prurigo nodularis completely upended her life. This experience led Sailaja to become a passionate and outspoken advocate, determined to see those with a rare disease receive the care and dedicated treatments they all need and deserve, on par with patients of mainstream conditions.
Sailaja is able to leverage a deep and broad skill set gained from a lengthy career in investment and central banking to her advocacy work.
Ms Sailaja Maganti discloses: Consulting fees from Galderma.
